TED Ted Baker Plc

RNS Number:8060Q
Tepnel Life Sciences PLC
05 September 2005




                            TEPNEL LIFE SCIENCES PLC
                                        
                     STATEMENT RE POSSIBLE OFFER FOR TEPNEL
                                        

Further to the announcement made on 14 July 2005, Tepnel Life Sciences PLC (AIM:
TED) ('Tepnel' or 'the Company') the UK-based international Research Products &
Services and Molecular Diagnostics group, announces today that talks with
potential offerors for the Company have been terminated by the Tepnel Board. The
Company continues to talk with various parties on a number of commercial
collaborations including distributorships and joint venture opportunities.

Whilst a proposed valuation of the Company received from a third party was above
the current share price, the Board believes that such a valuation underestimated
the present and future potential value of Tepnel. Consequently the Board of the
Company is not in a position to recommend to shareholders any of the proposals
made to the Company. The Board believes it has an excellent future as an
independent company and will continue to explore means of building and enhancing
returns to its shareholders.

The Board looks forward to updating shareholders of the further significant
progress in its financial performance when the interim results for the six
months ended 30 June 2005 are released in September. In a recent trading
statement issued in July, Tepnel announced that Group sales this year were
approximately 35% ahead of the same period last year at #6.85m (unaudited)
(2004: #5.07m). Sales for second quarter of the year were approximately #3.66m
(unaudited). The Company expects to maintain significant sales growth for the
remainder of the year.

Tepnel's management team is focused on delivering value to shareholders. The
Board of Tepnel firmly believes that the current strategy of the Group will
result in continued delivery of growth and excellent returns to shareholders.



About Tepnel

Tepnel is a UK based international biotechnology company. The Company has
laboratories, manufacturing and operations in the USA, UK and France with 175
employees. Tepnel provides test kits, reagents and services to two highly
synergistic markets, these being Molecular Diagnostics and Biomedical Research.
The company's strategy has been to identify high growth niche opportunities
within these multi-billion pound markets. Tepnel focuses on these niche
opportunities with internally developed products, patents, expertise and
know-how as well as strategic acquisitions, to develop a leadership position
within these defined market segments.

Enquiries:

Ben Matzilevich, Chief Executive Officer, Tepnel Life Sciences plc 0161 946 2200
Gron Ffoulkes-Davies, Finance Director, Tepnel Life Sciences plc   0161 946 2200
Mark Percy, Seymour Pierce Limited                                 0207 107 8000
Richard Anderson, De Facto Communications Ltd                      0207 940 1000




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
OTTPKBKDFBKDACK

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024